Posts Tagged ‘pharmaceutical research’

Are we on our way to progressing beyond weight loss as the primary end point for judging the value of new medicines in obesity? On this closing day of Obesity Care Week, topline results for a promising new obesity medicine – petrelentide – prompts us to reflect on this question. We suspect AI was making […]

Novo Nordisk unveiled the results of a commercially risky study of CagriSema for obesity yesterday and it was another tough break for Novo Nordisk. The study aimed to prove that – at worst – this next generation combination obesity drug is as good as tirzepatide. There was a slim hope was that it might prove […]

Yesterday, Roche announced topline results from a phase two study of a new injectable dual agonist medicine for obesity. The drug, CT-388, delivered a reduction in body weight of 22.5% after 48 weeks at the highest dose tested (24 mg). Placebo-subtracted weight loss was 18.3% and at 48 weeks, patients taking the drug were still […]

Reporting for the Washington Post, Daniel Gilbert tells us “the next frontier in weight-loss drugs is one-time gene therapy.” Setting aside his misuse of the “weight-loss” misnomer, should we take him seriously? How much can we expect from gene-based therapies for obesity? Scientifically Substantial The body of peer-reviewed evidence for genetic therapies in obesity is […]

While all eyes in obesity focused on the launch of a daily oral tablet for ongoing treatment, Arrowhead Pharmaceuticals brought us a little surprise yesterday. They presented early data from phase one studies of two gene silencing therapies for obesity. Though these data are quite preliminary, they offer a signal of great promise for a […]

Stepping back from the intense swirl of obesity care research at the ADA meeting just concluded, one thing stands out: People are having a very hard time following the thread of all this innovation. If you have any doubt, just scan the reports of investment analysts at the meeting. On one hand, they know they […]

Yesterday, Metsera presented investors with topline data from phase one studies of a new amylin analog for obesity that promises monthly dosing. This is an early stage drug known only by its code name – MET-233i. Metsera is a young biotech company, founded in 2022. The big news here: 8.4% placebo-subtracted weight loss after 36 […]

The first shall be last and the last shall be first. Right now, it seems that Novo Nordisk, the pharmaceutical company that was first to commit and break through with a major advance in obesity is now falling behind Eli Lilly and Company. This is a story of risk, reward, and caution in the competition […]

Regeneron announced tantalizing results for the combination of trevogrumab with semaglutide for losing fat while preserving muscle. With the combination of these two drugs, it appears that individuals might lose more fat mass and less muscle mass than with semaglutide alone. In short, the promise is for a better quality of weight loss, leaving people […]

Yesterday was a profoundly sad day for people who care about American greatness in health. With a measure of gratuitous cruelty, the U.S. Department of Health and Human Services slashed 10,000 jobs, wiping out a stunning breadth of health expertise at FDA, CDC, and NIH. Robert Califf, an international expert in clinical research and cardiovascular […]